Breaking Finance News

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has downgraded Enanta Pharmaceuticals Inc (NASDAQ:ENTA) to Hold in a statement released on 11/29/2016.

On 2/09/2016, Robert W. Baird released a statement about Enanta Pharmaceuticals Inc (NASDAQ:ENTA) dropped the target price from $36.00 to $22.00 that suggested a downside of -0.15%.

Showing a price of $31.29, Enanta Pharmaceuticals Inc (NASDAQ:ENTA) traded 0.00% even on the day. With the last stock close price up 29.06% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the same time period. ENTA has recorded a 50-day moving average of $26.43 and a 200-day moving average of $24.25. Volume of trade was up over the average, with 260,034 shares of ENTA changing hands over the typical 226,498

Performance Chart

Enanta Pharmaceuticals Inc (NASDAQ:ENTA)

With a total market value of $0, Enanta Pharmaceuticals Inc has price-earnings ratio of 27.69 with a one year low of $20.39 and a one year high of $35.06 .

More About Enanta Pharmaceuticals Inc (NASDAQ:ENTA)

Enanta Pharmaceuticals Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC). The Company is involved in a program to develop nucleotide inhibitors to HCV NS5B polymerase. In its NASH program, the Company is developing agonists of the farnesoid X receptor, or FXR, that are designed to bind to that receptor and then trigger a response from it. The Company is also engaged in a program in PBC, another disease of the liver that can result in liver damage, liver failure, or hepatocellular carcinoma. Its pipeline of products includes Paritaprevir, ABT-493, EDP-239, ABT-494 and EDP-494.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.